Diagnostic Workup of Adrenal Insufficiency: A Practical Guide

Abstract

Adrenal insufficiency (AI) remains a diagnostic challenge in clinical endocrinology due to its nonspecific presentation and potentially life-threatening sequelae if unrecognized. This review synthesizes current evidence and international guidelines, providing a practical and comprehensive approach to the diagnostic workup of AI. Emphasis is placed on epidemiology, pathophysiology, risk factors, clinical manifestations, and the optimal sequence of biochemical and dynamic testing. The article also addresses recent advances, emerging diagnostic modalities, and guideline-driven recommendations, aiming to equip clinicians with an evidence-based, mechanism-oriented framework for timely diagnosis and management.

Introduction

Adrenal insufficiency is a disorder characterized by inadequate production of glucocorticoids, and in some cases mineralocorticoids, by the adrenal cortex. Timely diagnosis is critical as untreated AI can result in adrenal crisis, a medical emergency. However, the non-specificity of symptoms and the complexity of diagnostic algorithms contribute to delays and misdiagnosis. This article delivers a structured, evidence-based approach to the diagnostic evaluation of AI, integrating clinical, biochemical, and dynamic testing considerations for frontline providers and endocrinology specialists.

Epidemiology / Disease Burden

AI is a rare but significant endocrine disorder. The prevalence of primary adrenal insufficiency (PAI) is estimated at 93–144 cases per million, with an incidence of 4–6 per million annually. Secondary AI, often due to pituitary or hypothalamic dysfunction, is more prevalent, particularly in patients with pituitary disease or chronic glucocorticoid therapy. The burden of undiagnosed or inadequately managed AI is substantial, with increased morbidity, reduced quality of life, and elevated mortality risk, especially from adrenal crisis. Recent registry data highlight persistent diagnostic delays, underscoring the need for heightened clinical suspicion and standardized workup protocols.

Pathophysiology

The pathophysiology of AI is determined by the underlying etiology. In PAI, destruction or dysfunction of the adrenal cortex leads to deficient cortisol and, often, aldosterone production. The most common cause in developed countries is autoimmune adrenalitis, while tuberculosis and other infections remain significant in endemic regions. Secondary AI results from impaired adrenocorticotropic hormone (ACTH) secretion due to pituitary or hypothalamic dysfunction, leading to isolated cortisol deficiency without aldosterone compromise. Exogenous glucocorticoid withdrawal is the leading cause of tertiary AI, reflecting hypothalamic-pituitary-adrenal (HPA) axis suppression.

Risk Factors

Recognized risk factors for AI include autoimmune polyendocrine syndromes, chronic glucocorticoid therapy (oral, inhaled, topical, or intra-articular), pituitary or hypothalamic tumors, pituitary surgery or irradiation, traumatic brain injury, and history of infiltrative, infectious, or metastatic disease involving the adrenal or pituitary glands. Genetic mutations affecting adrenal biosynthetic pathways (e.g., congenital adrenal hyperplasia, adrenoleukodystrophy) also predispose to AI. Awareness of these risk profiles is crucial for targeted screening and early intervention.

Clinical Features

The clinical presentation of AI is notoriously variable and often insidious. Common symptoms include fatigue, weight loss, anorexia, nausea, vomiting, abdominal pain, and myalgias. Hyperpigmentation is a hallmark of PAI due to elevated ACTH and melanocyte-stimulating hormone, while features like orthostatic hypotension and salt craving reflect aldosterone deficiency. In secondary or tertiary AI, mineralocorticoid function is preserved, and hyperpigmentation is absent. Acute adrenal crisis, precipitated by physiological stress, infection, or abrupt steroid withdrawal, manifests with shock, hyponatremia, hyperkalemia (in PAI), and hypoglycemia, necessitating prompt recognition and treatment.

Diagnosis

Diagnostic evaluation begins with clinical suspicion based on risk factors and symptomatology, followed by biochemical confirmation. Basal morning serum cortisol measurement (ideally between 6–8 am) is the initial screening test; values <3 mcg/dL (<83 nmol/L) are highly suggestive of AI, while >18 mcg/dL (>500 nmol/L) virtually exclude it in most settings. Intermediate results necessitate dynamic testing, most commonly the standard (250 mcg) ACTH stimulation test. A peak cortisol <18–20 mcg/dL (<500–550 nmol/L) at 30 or 60 minutes confirms AI. Plasma ACTH differentiates PAI (elevated ACTH) from central AI (low or inappropriately normal ACTH). Additional workup includes renin, aldosterone, and electrolytes for PAI, and pituitary imaging for central causes. Autoantibody screening and genetic testing may be indicated in select cases. Emerging modalities such as salivary cortisol and liquid chromatography-tandem mass spectrometry (LC-MS/MS) offer improved specificity and are being integrated into clinical protocols.

Treatment & Management

Management hinges on glucocorticoid replacement (hydrocortisone, cortisone acetate, or prednisolone) titrated to mimic physiological circadian rhythms, with dose adjustments during illness or stress. In PAI, mineralocorticoid (fludrocortisone) and, if needed, DHEA replacement are added. Patient education regarding stress dosing, emergency hydrocortisone self-injection, and medical alert identification is critical to prevent adrenal crisis. Long-term follow-up includes monitoring for overtreatment, underreplacement, comorbid autoimmune disorders, and optimizing quality of life. Treatment of underlying etiologies (e.g., infection, tumor) should be pursued where feasible.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the diagnosis and management of AI. Modified-release hydrocortisone formulations and continuous subcutaneous hydrocortisone infusion aim to better replicate physiological cortisol profiles and improve patient-reported outcomes. The role of LC-MS/MS in cortisol assays is expanding, enhancing diagnostic accuracy, especially in challenging cases. Novel biomarkers, including salivary cortisone, and automated ACTH assays are under investigation. Ongoing research into the HPA axis recovery following exogenous steroid cessation and genetic therapies for congenital forms holds promise for personalized management strategies.

Guideline Recommendations

International consensus guidelines, including those from the Endocrine Society and the European Society of Endocrinology, advocate for prompt biochemical confirmation of suspected AI using morning cortisol and ACTH stimulation tests, with tailored follow-up investigations based on etiology. Stress dosing protocols and patient education are universally endorsed. Long-term management should emphasize individualized glucocorticoid titration, regular monitoring for complications, and multidisciplinary care for associated autoimmune or genetic disorders. Guideline updates increasingly reflect the utility of emerging diagnostic modalities and therapies aimed at optimizing clinical outcomes and patient safety.

Conclusion

Adrenal insufficiency requires a high index of suspicion, a thorough understanding of pathophysiology, and a systematic, guideline-driven diagnostic approach. Advances in diagnostic modalities and novel therapeutic options are improving outcomes, but timely recognition and management remain the cornerstone of care. Clinicians should remain vigilant for risk factors and early symptoms, utilize evidence-based testing algorithms, and ensure comprehensive education and follow-up to minimize morbidity and prevent adrenal crisis.